See more : Ultima United Limited (UUL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Senstar Technologies Ltd. (SNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senstar Technologies Ltd., a leading company in the Security & Protection Services industry within the Industrials sector.
You may be interested
- Sky Quarry Inc. (SKYQ) Income Statement Analysis – Financial Results
- Shenzhen Changhong Technology Co., Ltd. (300151.SZ) Income Statement Analysis – Financial Results
- LIMAK DOGU ANADOLU (LMKDC.IS) Income Statement Analysis – Financial Results
- Innovative Solutions Ecosystem, S.A. (ISE.MC) Income Statement Analysis – Financial Results
- ASO International, Inc. (9340.T) Income Statement Analysis – Financial Results
Senstar Technologies Ltd. (SNT)
Industry: Security & Protection Services
Sector: Industrials
Website: https://www.senstartechnologies.com
About Senstar Technologies Ltd.
Senstar Technologies Ltd. develops, manufactures, markets, and sells perimeter intrusion detection sensors, physical barriers, video analytics and management systems, and security video observation and surveillance systems. The company offers Perimeter Intrusion Detection Systems (PIDS), fence mounted, buried, and free standing; PIDS fence sensor with intelligent perimeter LED based lighting; common operating platform for video management software, including intelligent video analytics applications, PIDS, and electronic access control systems; security thermal imaging observation and surveillance systems; and life safety or duress alarm systems. The company's products are used to protect borders and sensitive facilities, including military bases, power plants, air and sea ports, prisons, industrial sites, large retailer organizations, banks, and oil and gas facilities; sporting events, including athlete villages and stadiums, and municipalities from intrusion, terror, crime, sabotage or vandalism to infrastructure, assets and personnel. Senstar Technologies Ltd. sells its products through system integrators and distribution channels. The company was formerly known as Magal Security Systems Ltd. and changed its name to Senstar Technologies Ltd. in September 2021. Senstar Technologies Ltd. was incorporated in 1984 and is based in Ramat Gan, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.79M | 35.56M | 34.92M | 81.27M | 86.83M | 92.60M | 64.29M | 67.83M | 63.74M | 77.54M | 51.52M | 77.70M | 88.59M | 49.70M | 54.52M | 70.36M | 72.38M | 66.96M | 61.28M | 60.97M | 59.36M | 42.97M | 41.02M | 38.57M | 31.97M | 32.10M | 25.50M | 18.20M | 17.10M | 16.80M | 10.70M |
| Cost of Revenue | 13.94M | 14.06M | 12.94M | 46.71M | 48.07M | 52.30M | 32.97M | 34.57M | 32.72M | 43.05M | 31.06M | 44.16M | 49.09M | 31.40M | 33.33M | 49.21M | 43.51M | 40.23M | 39.15M | 33.73M | 33.38M | 23.92M | 21.51M | 20.52M | 15.26M | 15.20M | 12.00M | 9.90M | 8.80M | 8.50M | 5.50M |
| Gross Profit | 18.85M | 21.50M | 21.98M | 34.56M | 38.76M | 40.30M | 31.33M | 33.26M | 31.01M | 34.49M | 20.46M | 33.53M | 39.50M | 18.30M | 21.19M | 21.15M | 28.87M | 26.73M | 22.13M | 27.25M | 25.98M | 19.04M | 19.52M | 18.05M | 16.70M | 16.90M | 13.50M | 8.30M | 8.30M | 8.30M | 5.20M |
| Gross Profit Ratio | 57.48% | 60.47% | 62.95% | 42.52% | 44.64% | 43.52% | 48.72% | 49.03% | 48.66% | 44.48% | 39.71% | 43.16% | 44.59% | 36.82% | 38.86% | 30.06% | 39.88% | 39.92% | 36.11% | 44.69% | 43.77% | 44.32% | 47.57% | 46.79% | 52.25% | 52.65% | 52.94% | 45.60% | 48.54% | 49.40% | 48.60% |
| Research & Development | 4.01M | 4.03M | 3.93M | 5.66M | 6.37M | 6.85M | 6.56M | 6.78M | 4.81M | 4.60M | 4.41M | 4.04M | 3.90M | 4.11M | 4.82M | 6.20M | 5.76M | 5.38M | 5.27M | 4.68M | 4.77M | 3.13M | 3.05M | 2.98M | 2.68M | 2.30M | 2.00M | 2.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.98M | 6.97M | 9.71M | 9.45M | 11.14M | 7.85M | 7.45M | 7.03M | 8.90M | 7.79M | 7.41M | 8.68M | 7.59M | 8.22M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.95M | 9.01M | 10.00M | 13.83M | 16.90M | 18.56M | 18.16M | 17.54M | 14.79M | 17.13M | 12.78M | 16.53M | 19.42M | 11.26M | 10.88M | 17.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.11M | 15.99M | 16.97M | 23.54M | 26.35M | 29.70M | 26.01M | 24.98M | 21.81M | 26.03M | 20.57M | 23.94M | 28.10M | 18.85M | 19.09M | 30.65M | 20.40M | 18.61M | 19.14M | 18.45M | 16.89M | 13.58M | 12.88M | 11.79M | 9.92M | 10.40M | 8.20M | 4.20M | 6.30M | 5.70M | 3.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.11M | 20.02M | 20.90M | 29.20M | 32.72M | 36.55M | 32.57M | 31.76M | 26.63M | 30.63M | 24.98M | 27.98M | 29.69M | 22.96M | 23.91M | 36.84M | 26.10M | 23.99M | 24.41M | 24.33M | 21.66M | 16.71M | 15.94M | 14.77M | 14.03M | 14.10M | 12.30M | 6.80M | 6.90M | 6.30M | 4.20M |
| Cost & Expenses | 34.06M | 34.07M | 33.84M | 75.91M | 80.79M | 88.85M | 65.54M | 66.33M | 59.35M | 73.68M | 56.04M | 72.14M | 78.78M | 54.36M | 57.24M | 86.05M | 69.61M | 64.22M | 63.56M | 58.06M | 55.04M | 40.63M | 37.44M | 35.29M | 29.29M | 29.30M | 24.30M | 16.70M | 15.70M | 14.80M | 9.70M |
| Interest Income | 151.00K | 48.00K | 26.00K | 158.00K | 664.00K | 670.00K | 462.00K | 303.00K | 54.00K | 141.00K | 337.00K | 671.00K | 1.91M | 182.00K | 484.00K | 864.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 157.00K | 273.00K | 52.00K | 310.00K | 360.00K | 412.00K | 349.00K | 299.00K | 381.00K | 493.00K | 406.00K | 602.00K | 1.16M | 967.00K | 1.57M | 2.01M | 1.90M | 1.39M | 1.25M | 1.30M | 1.11M | 0.00 | 942.00K | 214.00K | 0.00 | 900.00K | 0.00 | 200.00K | 100.00K | 300.00K | 200.00K |
| Depreciation & Amortization | 917.00K | 1.43M | 1.87M | 1.96M | 2.10M | 2.25M | 1.88M | 1.74M | 1.50M | 1.97M | 1.72M | 1.18M | 1.22M | 1.06M | 1.20M | 3.06M | 2.14M | 2.21M | 2.40M | 2.15M | 1.40M | 1.11M | 1.43M | 1.38M | 1.43M | 1.40M | 2.10M | 600.00K | 600.00K | 600.00K | 500.00K |
| EBITDA | -255.00K | 3.06M | 1.94M | 3.99M | 6.47M | 7.36M | -2.98M | 2.94M | 6.92M | 5.86M | -2.34M | 6.87M | 12.94M | -3.62M | -2.26M | -13.59M | 4.91M | 4.94M | 125.00K | 5.22M | 5.68M | 3.45M | 5.01M | 4.67M | 4.10M | 4.20M | 3.31M | 2.10M | 2.00M | 2.60M | 1.50M |
| EBITDA Ratio | -0.78% | 4.17% | 3.10% | 6.59% | 6.95% | 4.05% | 1.70% | 2.20% | 6.89% | 8.13% | -8.77% | 7.15% | 14.61% | -9.38% | -4.99% | -17.95% | 8.79% | 8.34% | 0.62% | 10.21% | 10.60% | 8.02% | 12.22% | 12.10% | 14.57% | 13.08% | 20.39% | 11.54% | 11.70% | 15.48% | 14.02% |
| Operating Income | -1.27M | 54.00K | -788.00K | 3.40M | 3.94M | 3.76M | -1.24M | 1.50M | 4.39M | 1.42M | -4.52M | 5.56M | 9.81M | -4.66M | -2.72M | -28.58M | 2.77M | 2.74M | -2.28M | 2.92M | 4.32M | 2.33M | 3.58M | 3.28M | 2.67M | 2.80M | 1.20M | 1.50M | 1.40M | 2.00M | 1.00M |
| Operating Income Ratio | -3.86% | 0.15% | -2.26% | 4.18% | 4.54% | 4.05% | -1.93% | 2.20% | 6.89% | 1.84% | -8.77% | 7.15% | 11.07% | -9.38% | -4.99% | -40.62% | 3.83% | 4.09% | -3.72% | 4.78% | 7.28% | 5.43% | 8.73% | 8.51% | 8.36% | 8.72% | 4.71% | 8.24% | 8.19% | 11.90% | 9.35% |
| Total Other Income/Expenses | -64.00K | 141.00K | -1.01M | -1.02M | 3.78M | 1.36M | -3.96M | -591.00K | 642.00K | -595.00K | 59.00K | -472.00K | 756.00K | -967.00K | -1.57M | -16.03M | -2.20M | -851.00K | -800.00K | -762.00K | -1.00M | 199.00K | 40.00K | -214.00K | -484.00K | -205.00K | -1.91M | -200.00K | -100.00K | 0.00 | -200.00K |
| Income Before Tax | -1.33M | 1.63M | 70.00K | 3.90M | 4.37M | 5.12M | -5.21M | 904.00K | 5.03M | 3.40M | -4.46M | 5.09M | 10.57M | -5.63M | -4.29M | -30.59M | 569.00K | 1.89M | -3.06M | 2.15M | 3.32M | 2.53M | 3.62M | 3.07M | 2.19M | 2.60M | -700.00K | 1.30M | 1.30M | 0.00 | 800.00K |
| Income Before Tax Ratio | -4.05% | 4.57% | 0.20% | 4.80% | 5.04% | 5.52% | -8.10% | 1.33% | 7.89% | 4.39% | -8.66% | 6.54% | 11.93% | -11.32% | -7.87% | -43.48% | 0.79% | 2.82% | -4.99% | 3.53% | 5.59% | 5.90% | 8.82% | 7.96% | 6.85% | 8.10% | -2.75% | 7.14% | 7.60% | 0.00% | 7.48% |
| Income Tax Expense | -40.00K | -2.40M | 2.26M | 3.00M | 1.55M | 2.07M | 1.70M | -122.00K | 1.92M | 82.00K | 69.00K | 991.00K | 723.00K | 602.00K | 728.00K | 1.62M | 373.00K | 948.00K | -23.00K | 1.10M | 913.00K | 645.00K | 452.00K | 180.00K | 259.00K | 300.00K | 200.00K | 100.00K | 200.00K | 300.00K | 200.00K |
| Net Income | -1.29M | 3.83M | -2.19M | 902.00K | 2.29M | 2.95M | -6.91M | 1.03M | 3.14M | 3.41M | -4.46M | 4.09M | 9.84M | -6.21M | -855.00K | -32.60M | 1.88M | 810.00K | -3.21M | 1.05M | 2.40M | 1.89M | 3.17M | 2.89M | 1.93M | 2.30M | -900.00K | 1.20M | 1.10M | 1.70M | 600.00K |
| Net Income Ratio | -3.93% | 10.77% | -6.28% | 1.11% | 2.64% | 3.18% | -10.75% | 1.52% | 4.93% | 4.40% | -8.66% | 5.27% | 11.11% | -12.49% | -1.57% | -46.34% | 2.60% | 1.21% | -5.24% | 1.73% | 4.05% | 4.39% | 7.72% | 7.49% | 6.04% | 7.17% | -3.53% | 6.59% | 6.43% | 10.12% | 5.61% |
| EPS | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.21 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| EPS Diluted | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.20 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| Weighted Avg Shares Out | 21.48M | 23.31M | 23.21M | 23.15M | 23.13M | 23.04M | 22.99M | 18.00M | 17.29M | 17.12M | 17.07M | 16.92M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.02M | 8.69M | 9.25M | 9.18M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
| Weighted Avg Shares Out (Dil) | 23.31M | 23.31M | 23.21M | 23.15M | 23.14M | 23.29M | 22.99M | 18.03M | 17.35M | 17.28M | 17.07M | 16.95M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.25M | 8.90M | 9.25M | 9.27M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
Senesco Technologies Selects Criterium to Manage Multiple Myeloma Study
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company’s lead therapeutic candidate for the...
Senesco Technologies Told by FDA It May Proceed – SNS01-T IND is Open
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that the Company has been told by the U.S. Food and Drug Administration (the “FDA”) that all clinical hold issues have been satisfactorily addressed and the...
Senesco Technologies to Present at the 14th Annual Meeting of American Society of Gene and Cell Therapy
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that it will deliver a poster presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be...
Senesco Technologies Reports Third Quarter Fiscal 2011 Financial Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the third quarter ended March 31, 2011. Fiscal Third Quarter Highlights The Company submitted its first Investigational New Drug (“IND”) application with...
Senesco’s Lead Therapeutic Candidate SNS01-T Waiting for Update to Vendor’s Drug Master File
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT), announced today that the U.S. Food and Drug Administration (the "FDA") has informed the Company that its planned study in multiple myeloma is on hold until the...
Senesco Technologies to Present at the ROTH 23rd Annual OC Growth Stock Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) announced today that the Company will be presenting at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 4:30 p.m. Pacific Time...
Senesco Technologies Reports Second Quarter Fiscal 2011 Financial Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the second quarter ended December 31, 2010. During the quarter, the Company made significant headway towards advancement of its human therapeutics portfolio....
Senesco Technologies to Present at the 13th Annual BIO CEO & Investor Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Leslie J. Browne, Ph.D., the company’s President and Chief Executive Officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO &...
Senesco Technologies Announces IND Filing with FDA for SNS01-T
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for Senesco’s lead drug candidate SNS01-T...
Senesco Technologies to Present at American Association for Cancer Research’s Special Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that it will deliver a poster presentation at the American Association for Cancer Research’s Special Conference on Nano in Cancer: Linking Chemistry, Biology, and Clinical...
Source: https://incomestatements.info
Category: Stock Reports